DOCK2 and prostate cancer: DOCK2 mutations have been observed in many cancers, including chronic lymphocytic leukemia (CLL), prostate cancer, and acute myeloid leukemia (AML; Hasan et al., 2018; Bjerre et al., 2019; Hu et al., 2019).